Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel

This article was originally published in The Pink Sheet Daily

Executive Summary

Buyout of the private U.S. pharma company gives Sandoz a portfolio of generic drug candidates and technologies in asthma and COPD.
Advertisement

Related Content

'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
Respiratory Generics: Big Potential But A Tough Market To Crack
Respiratory Generics: Big Potential But A Tough Market To Crack
Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
FDA Proposes Bioequivalence Research On Inhalers, Other Complex Drugs
FDA Proposes Bioequivalence Research On Inhalers, Other Complex Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS070507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel